{"sent_idx": "91", "frame_idx": "1", "ev": "No deaths occurred during the study; one patient in MSE Dose Group 1 experienced serious AEs of chest pain and dyspnea when treated with buprenorphine.", "icos": [["0.4154911", "buprenorphine", "Buprenorphine", "deaths"], ["0.4154911", "buprenorphine", "buprenorphine", "deaths"], ["0.38367853", "buprenorphine", "MSE", "deaths"], ["0.056991145", "buprenorphine", "buccal buprenorphine", "deaths"], ["0.028692137", "buprenorphine", "buprenorphine .", "deaths"]], "sample": "c"}
{"sent_idx": "91", "frame_idx": "2", "ev": "No deaths occurred during the study; one patient in MSE Dose Group 1 experienced serious AEs of chest pain and dyspnea when treated with buprenorphine.", "icos": [["0.95720774", "buprenorphine", "Buprenorphine", "serious AEs of chest pain and dyspnea"], ["0.95720774", "buprenorphine", "buprenorphine", "serious AEs of chest pain and dyspnea"], ["0.69593203", "buprenorphine", "buprenorphine .", "serious AEs of chest pain and dyspnea"], ["0.61660886", "buprenorphine", "MSE", "serious AEs of chest pain and dyspnea"], ["0.18713395", "buprenorphine", "buccal buprenorphine", "serious AEs of chest pain and dyspnea"]], "sample": "c"}
{"sent_idx": "102", "frame_idx": "6", "ev": "The data did not suggest any difference in opioid withdrawal following BBUP and full \u03bc-opioid agonist administered at 50% of the therapeutic dose.", "icos": [["0.99921083", "BBUP", "around - the - clock full opioid agonist therapy", "opioid withdrawal"], ["0.9991394", "BBUP", "\u03bc - opioid agonist therapy", "opioid withdrawal"], ["0.9991109", "BBUP", "\u03bc - opioid agonist", "opioid withdrawal"], ["0.99888605", "BBUP", "active full \u03bc - opioid agonist", "opioid withdrawal"], ["0.9982876", "BBUP", "active full \u03bc - opioid agonist .", "opioid withdrawal"]], "sample": "c"}
{"sent_idx": "104", "frame_idx": "7", "ev": "Administration of 300- or 450-\u03bcg doses of BBUP 8 to 12 hours after the last dose of full \u03bc-opioid agonist was not associated with a higher incidence of serious AEs, AEs leading to discontinuation, or treatment-emergent AEs overall compared with the 50% dose of the prescribed full \u03bc-opioid agonist.", "icos": [["0.99952435", "BBUP", "BBUP", "treatment - emergent AEs"], ["0.9993857", "BBUP", "around - the - clock full opioid agonist therapy", "treatment - emergent AEs"], ["0.9992607", "BBUP", "\u03bc - opioid agonist therapy", "treatment - emergent AEs"], ["0.9992207", "BBUP", "active full \u03bc - opioid agonist .", "treatment - emergent AEs"], ["0.99921966", "BBUP", "active full \u03bc - opioid agonist", "treatment - emergent AEs"]], "sample": "c"}
{"sent_idx": "104", "frame_idx": "8", "ev": "Administration of 300- or 450-\u03bcg doses of BBUP 8 to 12 hours after the last dose of full \u03bc-opioid agonist was not associated with a higher incidence of serious AEs, AEs leading to discontinuation, or treatment-emergent AEs overall compared with the 50% dose of the prescribed full \u03bc-opioid agonist.", "icos": [["0.999514", "BBUP", "BBUP", "serious AEs , AEs leading to discontinuation"], ["0.99934524", "BBUP", "around - the - clock full opioid agonist therapy", "serious AEs , AEs leading to discontinuation"], ["0.999258", "BBUP", "\u03bc - opioid agonist therapy", "serious AEs , AEs leading to discontinuation"], ["0.9991823", "BBUP", "active full \u03bc - opioid agonist .", "serious AEs , AEs leading to discontinuation"], ["0.9991406", "BBUP", "\u03bc - opioid agonist", "serious AEs , AEs leading to discontinuation"]], "sample": "c"}
